A 6-Week Randomised Double-Blind, Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults With Major Depressive Disorder and Concomitant Anxiety.

Trial Profile

A 6-Week Randomised Double-Blind, Placebo-Controlled Study of BCI-540 80 mg q.d. and 80 mg t.i.d. in the Treatment of Adults With Major Depressive Disorder and Concomitant Anxiety.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2011

At a glance

  • Drugs Coluracetam (Primary)
  • Indications Anxiety; Depression; Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2010 Results have been reported in a Braincells media release.
    • 30 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 30 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top